The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 clinical trial investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of AB821 in adult patients with locally advanced or metastatic melanoma and other solid tumor malignancies (NCT 07027488).
 
Harriet Kluger
Consulting or Advisory Role - Genmab; GI Reviewers; Immunocore; Invox; Iovance Biotherapeutics; Replimune; Teva; TuHura; Werewolf Pharma
Research Funding - Apexigen (Inst); Asherbio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Apexigen
 
David Braun
Stock and Other Ownership Interests - CurIOS Therapeutics; Elephas Bio; Fortress Biotech (subsidiary)
Consulting or Advisory Role - 2nd.MD; Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Compugen; CurIOS Therapeutics; Daiichi Sankyo; Dedham Group; Defined Health; DLA Piper; Eisai; Eisai; Elephas Bio; Exelixis; GU Oncology Now; Insight Strategy; Link Cell Therapies; Merck; Neomorph; Nimbus Therapeutics; Octane Co.; Pfizer; Pfizer; Schlesinger Associates; Scholar Rock; Scholar Rock; Scholar Rock; Scholar Rock; SignifyMD; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ivana Djuretic
Employment - Asher Biotherapeutics
Leadership - Asher Biotherapeutics
Stock and Other Ownership Interests - Asher Biotherapeutics
Patents, Royalties, Other Intellectual Property - Issued and pending patents with CD8-targeted cytokines, including CD8-IL2/AB248 (Inst)
 
Michael Hurwitz
Employment - Arvinas (I); Faeth Therapeutics (I); Gamida Cell (I); Pfizer (I)
Stock and Other Ownership Interests - Arvinas (I)
Consulting or Advisory Role - Affini-T Therapeutics; Bristol-Myers Squibb/Celgene; crispr therapeutics; Exelixis; Janssen; Nektar; pliant; Regeneron; TScan Therapeutics
Research Funding - Achilles Therapeutics; Achilles Therapeutics; Apexigen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Endocyte; Endocyte; Genentech; Genmab; Innocrin Pharma; Iovance Biotherapeutics; Lilly; Lyell Immunopharma; Lyell Immunopharma; Merck; Nektar; Novartis; Novartis; Pfizer; Progenics; Sanofi/Aventis; Seagen; Synthekine; Torque; Unum Therapeutics; Xilio Therapeutics
 
Jeffrey Ishizuka
Stock and Other Ownership Interests - Curios Therapeutics
Consulting or Advisory Role - Danger Bio; Fortress Biotech; Ono Pharmaceutical; Phenomic AI; Rheos Medicines; Tango Therapeutics; Two River Group
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - I am an inventor on a patent on approaches targeting dsRNA sensing titled: "MODULATING dsRNA EDITING, SENSING, AND METABOLISM TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY AND/OR MODULATORS OF INTRATUMORAL INTERFERON".
 
David Schoenfeld
No Relationships to Disclose
 
Mario Sznol
Stock and Other Ownership Interests - Actym Therapeutics; Asher Biotherapeutics; EvolveImmune Therapeutics; GlaxoSmithKline; Intensity Therapeutics; Johnson & Johnson/Janssen; Nextcure; Normunity; Oncohost; Rootpath
Consulting or Advisory Role - Aulos; Biond Biologics; BioNTech; Bristol-Myers Squibb; Cullinan Oncology; DynamiCure Biotechnology; GII Innovation; IDEAYA Biosciences; Immatics; ImmunoGenesis; Innate Pharma; IO Biotech; Lyvgen Biopharma; Pfizer; Pliant; Regeneron; Sanofi; Simcha Therapeutics; Teva; Xilio Therapeutics
 
Mark Sayles
Employment - Amgen (I); Asher Biotherapeutics; TCG Labs Soleil
Stock and Other Ownership Interests - Amgen; Amgen (I); Arguello Biosciences; Asher Biotherapeutics; Balboa Biopharmaceuticals; Clement Therapeutics; Duboce Biopharmaceuticals; Janux Therapeutics; Juri Biosciences; Zentalis
 
Thuy Tran
No Relationships to Disclose